[go: up one dir, main page]

MX2016004239A - Anticuerpos anti-epcam y métodos de uso. - Google Patents

Anticuerpos anti-epcam y métodos de uso.

Info

Publication number
MX2016004239A
MX2016004239A MX2016004239A MX2016004239A MX2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A
Authority
MX
Mexico
Prior art keywords
antibody
scfv
fab
combination
immunoconjugate
Prior art date
Application number
MX2016004239A
Other languages
English (en)
Inventor
Macdonald Glen
Cizeau Jeannick
PREMSUKH Arjune
CHOONIEDASS Shilpa
Entwistle Joycelyn
Original Assignee
Viventia Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Bio Inc filed Critical Viventia Bio Inc
Publication of MX2016004239A publication Critical patent/MX2016004239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente invencion se refiere a composiciones de anticuerpos e inmunoconjugados que potencialmente carecen de epítopes de células T y provocan una respuesta inmunitaria reducida. El anticuerpo puede ser un fragmento de anticuerpo, tales como Fab, Fab´, F(ab´)2, scFv, dsFv, ds-scFv, dímeros, minicuerpos, diacuerpos, fragmentos de anticuerpo biespecíficos, multímeros, y cualquier combinación de los mismos. En una modalidad adicional, el anticuerpo puede unir a una molécula de adhesión de celulas epiteliales de antigeno (EpCAM). En otra modalidad, un inmunoconjugado puede comprender un anticuerpo unido a una molécula efectora, en donde la molécula efectora puede ser un radioisótopo, un agente antineoplásico, un inmunomodulador, un modificador de la respuesta biológica, lectina, una toxina, un cromóforo, un fluoróforo, un compuesto quimioluminiscente, una enzima, un ion de metal, y cualquier combinación de los mismos.
MX2016004239A 2013-10-02 2014-10-02 Anticuerpos anti-epcam y métodos de uso. MX2016004239A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885817P 2013-10-02 2013-10-02
US201462030805P 2014-07-30 2014-07-30
PCT/CA2014/050950 WO2015048901A1 (en) 2013-10-02 2014-10-02 Anti-epcam antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2016004239A true MX2016004239A (es) 2016-11-14

Family

ID=52778265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004239A MX2016004239A (es) 2013-10-02 2014-10-02 Anticuerpos anti-epcam y métodos de uso.

Country Status (18)

Country Link
US (1) US9822182B2 (es)
EP (1) EP3052525B1 (es)
JP (1) JP2017504621A (es)
KR (1) KR20160058954A (es)
CN (1) CN105764925A (es)
AU (1) AU2014331494A1 (es)
BR (1) BR112016007232A2 (es)
CA (1) CA2925915C (es)
DK (1) DK3052525T3 (es)
ES (1) ES2747273T3 (es)
HU (1) HUE046673T2 (es)
IL (1) IL244590A0 (es)
MX (1) MX2016004239A (es)
PL (1) PL3052525T3 (es)
PT (1) PT3052525T (es)
RU (1) RU2016116549A (es)
SG (1) SG11201602170XA (es)
WO (1) WO2015048901A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526219T3 (es) 2003-04-30 2015-01-08 Universität Zürich Procedimientos de tratamiento de cáncer usando una inmunotoxina
US9822182B2 (en) 2013-10-02 2017-11-21 Viventia Bio Inc. Anti-EPCAM antibodies and methods of use
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
HK1249020A1 (zh) 2015-03-12 2018-10-26 Viventia Bio Inc. 用於治疗epcam阳性膀胱癌的治疗方法
WO2017023704A1 (en) * 2015-07-31 2017-02-09 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
AU2020292304B2 (en) 2019-06-11 2023-03-30 Bioatla, Inc. Conditionally active anti-EpCam antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
EP4504275A1 (en) 2022-04-06 2025-02-12 Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) Epithelial cell adhesion molecule (epcam)-fluorescence imaging molecule for the detection of gastrointestinal tumors and cancer positive lymph nodes
KR20250155039A (ko) * 2023-03-02 2025-10-29 바이오아트라, 인코퍼레이티드 조건부 활성 항-epcam 항체, 항체 단편 및 이를 포함하는 작제물
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
CA2369622C (en) 1999-04-09 2011-06-14 Universitat Zurich Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
US20030148409A1 (en) 2001-10-15 2003-08-07 Edmund Rossi Direct targeting binding proteins
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
ES2526219T3 (es) 2003-04-30 2015-01-08 Universität Zürich Procedimientos de tratamiento de cáncer usando una inmunotoxina
WO2005090579A1 (en) 2004-03-19 2005-09-29 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
CN1954073B (zh) * 2004-03-19 2013-01-16 默克专利股份有限公司 被修饰Bouganin蛋白、细胞毒素及其方法和用途
EP2927322A1 (en) 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
NZ556055A (en) * 2004-12-21 2009-12-24 Viventia Biotech Inc Cancer specific antibody and cell surface proteins
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
WO2008052322A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
CA2684330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
US20140193436A1 (en) 2011-06-24 2014-07-10 Centrose, Llc Extracellular targeted drug conjugates
SG11201508419PA (en) 2013-04-12 2015-11-27 Viventia Bio Inc Compositions and methods for detection and treatment of hepatocellular carcinoma
US9822182B2 (en) 2013-10-02 2017-11-21 Viventia Bio Inc. Anti-EPCAM antibodies and methods of use
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Also Published As

Publication number Publication date
AU2014331494A1 (en) 2016-04-07
CA2925915C (en) 2023-05-02
HUE046673T2 (hu) 2020-03-30
US20160237164A1 (en) 2016-08-18
SG11201602170XA (en) 2016-04-28
BR112016007232A2 (en) 2018-01-23
CN105764925A (zh) 2016-07-13
EP3052525A1 (en) 2016-08-10
EP3052525B1 (en) 2019-07-24
RU2016116549A (ru) 2017-11-09
WO2015048901A1 (en) 2015-04-09
KR20160058954A (ko) 2016-05-25
JP2017504621A (ja) 2017-02-09
US9822182B2 (en) 2017-11-21
DK3052525T3 (da) 2019-10-07
ES2747273T3 (es) 2020-03-10
CA2925915A1 (en) 2015-04-09
PL3052525T3 (pl) 2020-03-31
IL244590A0 (en) 2016-04-21
EP3052525A4 (en) 2017-03-29
PT3052525T (pt) 2019-10-18

Similar Documents

Publication Publication Date Title
MX2016004239A (es) Anticuerpos anti-epcam y métodos de uso.
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
MX2014002097A (es) Anticuerpos bioespecificos especificos para antigenos que activan celulas t y un antigeno tumoral y metodos de uso.
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
CR20110577A (es) Proteínas de unión a il-1
MX2016006572A (es) Construcciones de union a antigenos biespecificas dirigidas a her2.
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
MX361502B (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano.
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
EA201691321A1 (ru) Антитела и способы их применения
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
RU2012127077A (ru) Методика проведения иммунохроматографического анализа для серодиагностики